Retatrutide is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Retatrutide (Retatrutide (LY3437943)) is researched primarily for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers. The first triple hormone agonist targeting three distinct metabolic pathways simultaneously — producing superior weight loss compared to both semaglutide (single) and tirzepatide (dual) agonists. It belongs to the Triple hormone receptor agonist category of compounds.
What Is Retatrutide?
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist. Novel synthetic peptide developed by Eli Lilly targeting GIP, GLP-1, AND glucagon receptors simultaneously.
The first triple hormone agonist targeting three distinct metabolic pathways simultaneously — producing superior weight loss compared to both semaglutide (single) and tirzepatide (dual) agonists. It has attracted significant research interest for its potential effects on substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers.
How Does Retatrutide Produce These Benefits?
Activates GIP, GLP-1, and glucagon receptors simultaneously for synergistic metabolic effects: GLP-1R delays gastric emptying and reduces appetite, GIPR enhances glucose-dependent insulin secretion, and glucagon receptor activation increases energy expenditure and hepatic glucose regulation. The triple mechanism produces greater weight loss than dual agonists.
This multi-pathway activity is why Retatrutide shows potential across several different applications rather than being limited to a single use case.
Can Retatrutide Help With Substantial Weight Loss (Up To 24.2%)?
Research suggests Retatrutide may support substantial weight loss (up to 24.2%) through its triple hormone receptor agonist activity. Phase 3 TRIUMPH-4 reported 71.2 lb average weight loss (December 2025). Diabetes trial (TRIUMPH-1) showed 16.8% weight loss. Seven Phase 3 trials with results expected by year-end 2026. Over 20 ongoing clinical trials.
Protocols targeting substantial weight loss (up to 24.2%) typically use 4-12 mg weekly (maintenance after titration) administered once weekly for 48+ weeks (continuous therapy in trials).
Can Retatrutide Help With Improved Glycemic Control?
Research suggests Retatrutide may support improved glycemic control through its triple hormone receptor agonist activity. Phase 3 TRIUMPH-4 reported 71.2 lb average weight loss (December 2025). Diabetes trial (TRIUMPH-1) showed 16.8% weight loss. Seven Phase 3 trials with results expected by year-end 2026. Over 20 ongoing clinical trials.
Protocols targeting improved glycemic control typically use 4-12 mg weekly (maintenance after titration) administered once weekly for 48+ weeks (continuous therapy in trials).
Can Retatrutide Help With Improved Liver Steatosis?
Research suggests Retatrutide may support improved liver steatosis through its triple hormone receptor agonist activity. Phase 3 TRIUMPH-4 reported 71.2 lb average weight loss (December 2025). Diabetes trial (TRIUMPH-1) showed 16.8% weight loss. Seven Phase 3 trials with results expected by year-end 2026. Over 20 ongoing clinical trials.
Protocols targeting improved liver steatosis typically use 4-12 mg weekly (maintenance after titration) administered once weekly for 48+ weeks (continuous therapy in trials).
Can Retatrutide Help With Reduced Diabetic Kidney Disease Markers?
Research suggests Retatrutide may support reduced diabetic kidney disease markers through its triple hormone receptor agonist activity. Phase 3 TRIUMPH-4 reported 71.2 lb average weight loss (December 2025). Diabetes trial (TRIUMPH-1) showed 16.8% weight loss. Seven Phase 3 trials with results expected by year-end 2026. Over 20 ongoing clinical trials.
Protocols targeting reduced diabetic kidney disease markers typically use 4-12 mg weekly (maintenance after titration) administered once weekly for 48+ weeks (continuous therapy in trials).
Can Stacking Enhance Retatrutide Benefits?
Triple agonism provides inherent synergy — not typically stacked with other GLP-1 or GIP agonists.
See our Retatrutide stacking guide for detailed combination protocols.
What Is the Bottom Line on Retatrutide Benefits?
Retatrutide is researched for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers. The evidence base includes: Phase 3 TRIUMPH-4 reported 71.2 lb average weight loss (December 2025). Diabetes trial (TRIUMPH-1) showed 16.8% weight loss. Seven Phase 3 trials with results expected by year-end 2026. Over 20 ongoing clinical trials.
Retatrutide is not fda-approved as of march 2026. nda filing expected late 2026-early 2027. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
Retatrutide : Benefits, Dosage, Side Effects & Research
Related Reading
- Retatrutide Dosage Guide
- Retatrutide Side Effects
- Retatrutide Stacking Guide
- Retatrutide Cycle Guide
- Retatrutide Research
- CJC-1295 Complete Guide
Calculate Your Retatrutide Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Retatrutide.
Open Calculator →Research-Grade Sourcing
If you're going to research Retatrutide, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Retatrutide?
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist. Novel synthetic peptide developed by Eli Lilly targeting GIP, GLP-1, AND glucagon receptors simultaneously. It is researched for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers.
What is the recommended Retatrutide dosage?
Common dosages: 4-12 mg weekly (maintenance after titration) administered once weekly via subcutaneous injection. Cycle length: 48+ weeks (continuous therapy in trials). Half-life: approximately 4-5 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of Retatrutide?
Gastrointestinal effects predominate: diarrhea, vomiting, constipation, nausea. Generally manageable and dose-dependent. Potential pancreatitis risk similar to GLP-1 agonists.
Is Retatrutide safe?
Retatrutide has shown a preliminary safety profile in research. Not FDA-approved as of March 2026. NDA filing expected late 2026-early 2027. All research should follow appropriate safety protocols.